Schizophrenia: Neural mechanisms for novel therapies

Research output: Contribution to journalArticle

Abstract

Although valuable antischizophrenic drugs exist, they only partially ameliorate symptoms and elicit substantial side effects. Classic neuroleptic drugs act by blocking dopamine receptors. They can relieve some symptoms but not behavioral withdrawal features that are designated "negative" symptoms. Clozapine and related newer atypical neuroleptics may be more efficacious in relieving negative symptoms. Understandng their actions may facilitate new drug discovery. Agents influencing glutamate neurotransmission and N-methyl-D-aspartate receptors, especially the cotransmitter D-serine, are promising. Stimulation of the α7 subtype of nicotinic acetylcholine receptor may also be efficacious. The search for genes linked to schizophrenia has revealed several leads that may permit development of novel therapeutic agents. Promising genes include disrupted-in-schizophrenia-1, dysbindin, and neuregulin.

Original languageEnglish (US)
Pages (from-to)3-9
Number of pages7
JournalMolecular Medicine
Volume9
Issue number1-2
StatePublished - Jan 2003

Fingerprint

Antipsychotic Agents
Schizophrenia
Excitatory Amino Acid Agents
Neuregulin-1
Behavioral Symptoms
Clozapine
Dopamine Receptors
Nicotinic Receptors
Drug Discovery
N-Methyl-D-Aspartate Receptors
Synaptic Transmission
Serine
Genes
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Genetics

Cite this

Schizophrenia : Neural mechanisms for novel therapies. / Sawa, Akira; Snyder, Solomon H.

In: Molecular Medicine, Vol. 9, No. 1-2, 01.2003, p. 3-9.

Research output: Contribution to journalArticle

@article{8f9b447e8ba140879091d97708c1f887,
title = "Schizophrenia: Neural mechanisms for novel therapies",
abstract = "Although valuable antischizophrenic drugs exist, they only partially ameliorate symptoms and elicit substantial side effects. Classic neuroleptic drugs act by blocking dopamine receptors. They can relieve some symptoms but not behavioral withdrawal features that are designated {"}negative{"} symptoms. Clozapine and related newer atypical neuroleptics may be more efficacious in relieving negative symptoms. Understandng their actions may facilitate new drug discovery. Agents influencing glutamate neurotransmission and N-methyl-D-aspartate receptors, especially the cotransmitter D-serine, are promising. Stimulation of the α7 subtype of nicotinic acetylcholine receptor may also be efficacious. The search for genes linked to schizophrenia has revealed several leads that may permit development of novel therapeutic agents. Promising genes include disrupted-in-schizophrenia-1, dysbindin, and neuregulin.",
author = "Akira Sawa and Snyder, {Solomon H}",
year = "2003",
month = "1",
language = "English (US)",
volume = "9",
pages = "3--9",
journal = "Molecular Medicine",
issn = "1076-1551",
publisher = "Feinstein Institute for Medical Research",
number = "1-2",

}

TY - JOUR

T1 - Schizophrenia

T2 - Neural mechanisms for novel therapies

AU - Sawa, Akira

AU - Snyder, Solomon H

PY - 2003/1

Y1 - 2003/1

N2 - Although valuable antischizophrenic drugs exist, they only partially ameliorate symptoms and elicit substantial side effects. Classic neuroleptic drugs act by blocking dopamine receptors. They can relieve some symptoms but not behavioral withdrawal features that are designated "negative" symptoms. Clozapine and related newer atypical neuroleptics may be more efficacious in relieving negative symptoms. Understandng their actions may facilitate new drug discovery. Agents influencing glutamate neurotransmission and N-methyl-D-aspartate receptors, especially the cotransmitter D-serine, are promising. Stimulation of the α7 subtype of nicotinic acetylcholine receptor may also be efficacious. The search for genes linked to schizophrenia has revealed several leads that may permit development of novel therapeutic agents. Promising genes include disrupted-in-schizophrenia-1, dysbindin, and neuregulin.

AB - Although valuable antischizophrenic drugs exist, they only partially ameliorate symptoms and elicit substantial side effects. Classic neuroleptic drugs act by blocking dopamine receptors. They can relieve some symptoms but not behavioral withdrawal features that are designated "negative" symptoms. Clozapine and related newer atypical neuroleptics may be more efficacious in relieving negative symptoms. Understandng their actions may facilitate new drug discovery. Agents influencing glutamate neurotransmission and N-methyl-D-aspartate receptors, especially the cotransmitter D-serine, are promising. Stimulation of the α7 subtype of nicotinic acetylcholine receptor may also be efficacious. The search for genes linked to schizophrenia has revealed several leads that may permit development of novel therapeutic agents. Promising genes include disrupted-in-schizophrenia-1, dysbindin, and neuregulin.

UR - http://www.scopus.com/inward/record.url?scp=0037530516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037530516&partnerID=8YFLogxK

M3 - Article

C2 - 12765334

AN - SCOPUS:0037530516

VL - 9

SP - 3

EP - 9

JO - Molecular Medicine

JF - Molecular Medicine

SN - 1076-1551

IS - 1-2

ER -